<DOC>
	<DOCNO>NCT00138320</DOCNO>
	<brief_summary>The purpose study look antibody ( proteins body 's infection fighting system ) blood baby deliver woman participant Herpevac Trial Women , vaccinate either two three dos ( GlaxoSmithKline ) GSK candidate vaccine gD2t/alum-MPL hepatitis A vaccine . The goal study compare herpes hepatitis A antibody level newborns mother , see much antibody still present baby two six month birth . Approximately 2 teaspoon ( 10 ml ) mother 's blood collect time delivery within 15 day delivery . Approximately 2 teaspoon blood collect child 's umbilical cord time delivery , 1 teaspoon ( 3-5 ml ) child 's blood drawn within 15 day birth . Optional blood draw baby may occur 2 6 month birth .</brief_summary>
	<brief_title>Herpevac Neonatal Substudy</brief_title>
	<detailed_description>The primary objective study quantitate HSV-2 binding neutralize antibody titer sera newborn deliver HSV-uninfected woman vaccinate either two three dos GSK candidate vaccine gD2t/alum-MPL compare HSV-2 binding neutralize antibody titer newborns mother . Secondary objective : 1 ) evaluate durability HSV-2 binding neutralize antibody titer sera newborn deliver HSV-uninfected woman vaccinate either two three dos GSK candidate vaccine gD2t/alum-MPL ; 2 ) quantitate hepatitis A binding antibody titer sera newborn deliver woman vaccinate either two three dos HavrixÂ® hepatitis A vaccine ( control vaccine use Herpevac Trial Women ) , compare hepatitis A binding antibody titer newborns mother , evaluate durability hepatitis A binding antibody newborn . The sample size study determine base experience likely 50 woman . Optional additional blood collect mother infant 2 mo 6 mo delivery .</detailed_description>
	<mesh_term>Herpes Simplex</mesh_term>
	<criteria>1 . Enrolled Herpevac Trial Women . 2 . Has receive least two dos either candidate control vaccine . 3 . Pregnant . 4 . Written inform consent obtain participant . 5 . Willing blood collect either time delivery within 15 day delivery . If blood collect health care provider preside delivery , participant must willing give permission study personnel contact health care provider arrange collection blood . 6 . Willing either umbilical vein blood collect time delivery blood collect neonate within 15 day delivery . If blood collect umbilical vein , participant must willing give permission study personnel contact preside health care provider arrange collection blood . 7 . A participant investigator believe comply requirement protocol . 1 . Termination pregnancy , live birth . 2 . Entry violation Herpevac Trial Women enrollment . 3 . Receipt immunoglobulin blood product within 4 month prior expect date delivery . 4 . History current clinical evidence herpes simplex virus infection . Maternal withdrawal criterion : If follow occur enrollment , subject withdrawn prior obtain blood sample : 1 . Termination pregnancy , live birth . 2 . Determination subject enrol Herpevac Trial Women violation study 's entry criterion . 3 . Receipt immunoglobulin blood product within 4 month prior expect actual date delivery . 4 . Inability collect umbilical vein blood time delivery neonatal blood within 15 day birth due logistical reason . Infant withdrawal criterion : If follow occurs study , 2 6month blood sample ( 6month sample occurrence follow 2month blood draw ) collect infant : 1 . Participant [ mother ] chooses participate , continue participation , optional arm study . 2 . Inability collect neonatal blood within 15 day birth due logistical reason infant umbilical vein blood collect . 3 . Death infant . 4 . Adoption infant prior completion study . 5 . At discretion investigator . 6 . Receipt immunoglobulin blood product infant prior blood draw .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Herpes Simplex , vaccine , antibody , mother</keyword>
</DOC>